HBV相关肝癌TACE术后HBV DNA及肝功能变化的研究进展

Research progress on HBV DNA and liver function changes after TACE of HBV-induced hepatocellular carcinoma

对于不可切除的肝细胞肝癌(HCC),肝动脉化学治疗栓塞术(TACE)是一重要治疗手段。大多数HBV相关性HCC患者有肝纤维化或肝硬化等基础性疾病,TACE有可能导致HBV再激活,诱发慢性肝炎急性发作,甚至引发肝功能失代偿。目前有关TACE对HBV变化影响的报道不多,且临床上对于抗病毒治疗在TACE中的应用尚无统一指南。为了总结相关的研究进展,该文综述了HBV相关性HCC患者TACE术后HBV DNA和肝功能的变化情况。

Transcatheter arterial chemoembolization（ TACE） is an important therapeutic modality for unresectable hepatocellular carcinoma（ HCC）. A majority of patients diagnosed with HBV（ hepatitis B virus）-related HCC suffered from liver fibrosis or cirrhosis. TACE may have a potential to reactivate HBV,induce acute onset of chronic hepatitis or even hepatic decompensation. Currently,few studies reported the effect of TACE upon HBV variations. There is no consensus guideline on the application of anti-viral therapy in TACE in clinical settings. In this article,the changes in the HBV DNA and liver function after TACE in HBV-related HCC patients were briefly summarized.